Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Sheela Kolluri"'
Publikováno v:
The AAPS Journal
Graphical abstract Over the past decade, artificial intelligence (AI) and machine learning (ML) have become the breakthrough technology most anticipated to have a transformative effect on pharmaceutical research and development (R&D). This is partial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66050b792ac227be99f7aa9a1c6ebcfd
https://pubmed.ncbi.nlm.nih.gov/34984579
https://pubmed.ncbi.nlm.nih.gov/34984579
Autor:
W. Wolfgang Fleischhacker, Robert F. Reynolds, Jamie Geier, Sheela Kolluri, Brian L. Strom, John M. Kane, Onur N. Karayal, Sybil M. Eng
Publikováno v:
The Journal of Clinical Psychiatry. 75:e184-e190
OBJECTIVE: To characterize subgroups of subjects with schizophrenia from the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) trial who either completed or attempted suicide and those who did not. METHOD: The ZODIAC, conducted between Feb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f2ee2afe5bb75a6c1bfffccec812d69
https://doi.org/10.4088/jcp.13m08563
https://doi.org/10.4088/jcp.13m08563
Publikováno v:
Journal of Clinical Psychopharmacology. 33:425-431
OBJECTIVE This study aimed to examine the risk difference (RD) in the discontinuation due to adverse events, akathisia, overall extrapyramidal symptoms (EPS), reported-somnolence, and 7% or greater weight gain between ziprasidone monotherapy and plac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0acf57a06337c9323ecf2f55af5697ab
https://doi.org/10.1097/jcp.0b013e3182917f3f
https://doi.org/10.1097/jcp.0b013e3182917f3f
Autor:
Douglas Vanderburg, Mary Bachinsky, Onur N. Karayal, Sheela Kolluri, Suzanne Edman, Gary S. Sachs, Idil Cavus
Publikováno v:
The Journal of Clinical Psychiatry. 73:1420-1425
OBJECTIVES High failure rates of randomized controlled trials (RCTs) are well recognized but poorly understood. We report exploratory analyses from an adjunctive ziprasidone double-blind RCT in adults with bipolar I disorder (reported in part 1 of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b3f51604865b2f49d50b3e73ea47d2e
https://doi.org/10.4088/jcp.11m07389
https://doi.org/10.4088/jcp.11m07389
Publikováno v:
The Journal of Clinical Psychiatry. 73:e742-e748
Background Elevated cardiometabolic morbidity and mortality in patients with schizophrenia and bipolar disorder have been attributed to multiple sources, including antipsychotic treatment, which may adversely affect cardiometabolic risk factors. We t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5670b212f29ada2752189e098c46de9c
https://doi.org/10.4088/jcp.10r06802
https://doi.org/10.4088/jcp.10r06802
Autor:
Thomas G. Tensfeldt, A. John Camm, Sheela Kolluri, John M. Kane, Herbert Y. Meltzer, Cedric O'Gorman, J.J. Miceli, Onur N. Karayal
Publikováno v:
CNS Drugs. 26:351-365
Background: Prolongation of the corrected QT interval (QTc) is understood to be a predictor of risk for ventricular arrhythmia; consequently, data on QTc effects of drugs are used by regulatory bodies to evaluate potential safety risks. Clinical phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e6cb2634bc24ff39e43978141e66759
https://doi.org/10.2165/11599010-000000000-00000
https://doi.org/10.2165/11599010-000000000-00000
Autor:
Brinda Tammara, Sheela Kolluri, Satoshi Shoji, Judith Hey-Hadavi, Daniela J. Conrado, Ricardo Rojo, Dorothy McCabe, Sriram Krishnaswami
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 43(3)
PF-04171327 is a dissociated agonist of the glucocorticoid receptor (DAGR) being developed to retain anti-inflammatory efficacy while reducing unwanted effects. Our aim was to conduct a longitudinal dose–response analysis to identify the DAGR doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::797e83b02874a2fe877e9461a2c7a1cf
https://pubmed.ncbi.nlm.nih.gov/27178257
https://pubmed.ncbi.nlm.nih.gov/27178257
Autor:
Sybil M. Eng, Sheela Kolluri, Charlotte Kremer, John Camm, Brian L. Strom, Robert F. Reynolds, Michael A Lewis, Jamie Geier, Martin G. Keane, Onur N. Karayal
Publikováno v:
Pharmacoepidemiology and Drug Safety. 20:1192-1198
Purpose The Ziprasidone Observational study of car DIAC Outcomes (ZODIAC), a large simple trial comparing ziprasidone versus olanzapine in real-world use, showed no difference in risk of sudden death. Upon the request of the US Food and Drug Administ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c665269b6969ae1e78f2984c0b8279ed
https://doi.org/10.1002/pds.2185
https://doi.org/10.1002/pds.2185
Publikováno v:
Human Psychopharmacology: Clinical and Experimental. 26:282-290
Objective We examine data from short-term placebo-controlled and comparator-controlled clinical trials of ziprasidone in schizophrenia to confirm the predictive capacity of early symptom changes for response. We pose the question of how early is too
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e1df7b191bb2a402cf765a9d77e2df1
https://doi.org/10.1002/hup.1200
https://doi.org/10.1002/hup.1200
Publikováno v:
Australian & New Zealand Journal of Psychiatry. 44:697-705
Objective: Continuation therapy with antidepressants is recommended for depressed patients who have responded to initial treatment. We quantified its efficacy in preventing relapse of depression in a meta-analysis of 54 double-blind placebo-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515c2c6de748736467149776ba0b2764
https://doi.org/10.3109/00048671003705441
https://doi.org/10.3109/00048671003705441